Cell Therapeutics (CTIC) plummets 21% premarket following the pricing of its offering of 60K...

|About: CTI BioPharma Corp. (CTIC)|By:, SA News Editor

Cell Therapeutics (CTIC) plummets 21% premarket following the pricing of its offering of 60K shares of convertible preferred stock. Each share is convertible into about 714 shares of common  stock at a price of $1.40, making a total of approximately 42.9M shares. The current outstanding float is 52.25M shares. (PR)